Hedgehog signaling
The Hedgehog (Hh) pathway was first identified in the fruit fly Drosophila melanogaster in 1980 as a critical developmental signaling pathway regulating the proliferation, migration and differentiation of embryonic cells in a spatial-, temporal-and concentration-dependent manner. 1, 2 The functional role of Hh signaling is highly conserved across vertebrates during embryonic development. In adult tissues, the pathway is silenced, with the exception of tissue regeneration and repair following injury. 3, 4 In humans, the Hh family of proteins consist of three distinct ligands, Sonic (Shh), Indian (Ihh) and Desert (Dhh) Hedgehog, which are processed intracellularly from a precursor peptide of B45 kDa to generate an N-terminal secreted peptide (B20 kDa) that is retained close to the plasma membrane and a C-terminal glycosylated more diffusible peptide (B27 kDa). Of the three Hh ligands, Ihh is found most specifically within hematopoietic cells. In the absence of Hh ligands, the 12-transmembrane receptor Patched (Ptch) functions as an antagonist of the pathway by inhibiting the activation of Smoothened (Smo), a 7-transmembrane G-like protein coupled receptor. The nature of the interaction between Ptch and Smo remains poorly understood, but studies have suggested that they do not physically interact within the plasma membrane. Instead, it has been proposed that Ptch prevents Smo translocation into the primary cilium, 5, 6 by modulating the production or transport of small molecules 7 such as oxysterols. 8, 9 Once Hh binds to Ptch, the inhibition of Smo is relieved, allowing Smo to translocate to the primary cilium and activate members of the Gli family of zincfinger transcription factors (Gli1 and Gli2 which function mostly as activators, while Gli3 as a repressor; Figure 1 ). After stabilization and activation in the cilium, Gli translocates to the nucleus to regulate the transcription of Hh target genes including Gli1, Gli2 and Ptch as well as regulators of cell proliferation and survival. [10] [11] [12] Hh pathway and normal hematopoiesis Although the role of Hh signaling is most well understood in embryonic development, its role in the hematopoietic system is still incompletely defined and the subject of some controversy. Its role may be highly context dependent, changing with developmental stage (primitive vs early definitive vs late definitive hematopoiesis), species, cell type (hematopoietic stem cells (HSCs) vs progenitors vs differentiated cells), and even physiologic state (stress vs normal hematopoiesis). An excellent review focusing solely on the role of Hh in normal hematopoiesis was recently published. 13 In vertebrates, two waves of hematopoiesis occur during embryonic development: primitive, which in mice, begins at embryonic day 7.5 (E7.5) in the yolk sac; and definitive, which in mice, starts at E10.5 in the aorta-gonad-mesonephros (AGM) region.
During the primitive phase, evidence from genetic knockouts suggests that the Hh pathway appears to be mostly involved in vasculogenesis, rather than in hematopoiesis, per se. Ihh is expressed in the visceral endoderm surrounding the epiblast and within the endodermal layer of the mature yolk sac starting at E6.5 and induces the expression of Ptch and Gli1 in the mesoderm. 14, 15 Several groups have shown that Ihh À/À mouse embryos have yolk sac abnormalities 15, 16 with reduced vascularization and vascular disorganization. Fifty percent of these embryos die in misgestation and the reminder at birth. 16 In contrast, Smo À/À embryos die before E9.5, with multiple defects, including cardiac and gastrointestinal defects and cyclopia. 17 They exhibit a more severe yolk sac phenotype than Ihh À/À (ref. 18) embryos, arresting at the earlier vascular plexus stage with complete lack of angiogenesis, suggesting that other Hh ligands besides Ihh may be having a role. Subsequent work has identified the activation of Bmp4 by the Hh pathway, via Foxf1, in the mesoderm as responsible for primary vascular tube formation in the yolk sack. 19 Despite the significant defects in vasculogenesis, Ihh À/À embryos at E11.5 were not anemic, a time at which primitive hematopoiesis still supplies all circulating blood cells, 20 and that even E9.5 Smo À/À embryos proceeded with primitive erythropoiesis. 18 Definitive hematopoiesis is characterized by the formation of multipotent HSCs capable of engrafting adult recipients which, in the mouse, begins in the AGM at E10.5. 21 Very early in definitive hematopoiesis, Peeters et al. 22 have demonstrated that HSCs are definitively derived from AGM tissue and increased in number by signals from the neighboring ventral embryonic gut tissue, using AGM:gut explants. Then, they showed that the gut tissue expressed all three Hh ligands and exogenous addition of Hh ligands could induce the E10 AGM to produce transplantable HSCs. Supporting this, they could also block the production of transplantable HSCs with a Hh-specific antibody (5E1) on E10 AGM:gut explants. Very interestingly, the same antibody could not abrogate HSC production on E11 AGM:gut explants, suggesting Hh's role in definitive hematopoiesis may be highly time dependent.
Later in definitive hematopoiesis, HSC production shifts to fetal liver. Consistent with the idea that Hh loss affects the production of HSC, Cridland et al. 20 showed that in Ihh À/À mice there is anemia and a severe impairment in definitive erythropoiesis at E13.5, associated with markedly small fetal livers, in contrast to E11.5, when there is no defect in primitive hematopoiesis. Interestingly, there was minimal disturbance of HSC and progenitor compartments by immunophenotype and in vitro colony assays, which may be related to the specificity of Ihh. Abrogation of the Hh pathway at different time points using the naturally occurring Hh inhibitor cyclopamine in zebrafish embryos also supports the essential role of pathway activity in early definitive but not primitive hematopoiesis. report any effect in long-term HSC as observed by Trowbridge et al. 24 Supporting these studies, Zhao et al. 26 conditionally deleted Smo in hematopoietic cells by crossing mice carrying a loxPflanked Smo allele to vav-cre mice. The vav promoter is active in fetal and adult hematopoietic and endothelial cells and presumably in HSC. Although the frequency of HSCs and differentiated cells were normal in the Smo-deficient mice, these mice had a clear defect in long-term HSC function in primary and secondary transplants.
Further downstream of Smo and Ptch, Merchant et al.
27
studied the role of Gli1 in definitive hematopoiesis using a Gli1 À/À mouse model. Although Gli2 À/À mice show profound developmental defects and embryonic lethality, Gli1
À/À mice show no gross developmental defects. After a detailed analysis of HSCs and progenitors, they observed that the Gli1 À/À mice, in contrast to transplanted Smo À/À fetal liver, have more long-term HSCs that are quiescent and showed increased short-and longterm engraftment after transplantation. These observations suggested that Smo and Gli inhibition are not equivalent. In addition, myeloid response to granulocyte colony-stimulating factor was impaired in vivo and there was compromised leukocyte recovery after chemotherapy, demonstrating the role of Gli1 in stress hematopoiesis. 27 Bhardwaj et al. 28 found that human cord blood HSC and stromal cells of the hematopoietic microenvironment express Hh, Ptch and Smo as well as Gli1, Gli2 and Gli3. However, Gli1, Gli2 and Gli3 were not expressed in lineage restricted hematopoietic cells, which again suggests that the Hh pathway may be important only in the early stages of hematopoiesis. They showed that cytokine-induced proliferation of human cord blood HSC could be inhibited with antibodies to Hh (5E1 and APG6), whereas adding exogenous Shh stimulated the proliferation of cord blood HSC retaining the ability to engraft in immunodeficient nonobese diabetic/severe combined immunodeficiency mice.
In contrast to the studies that support the role for Hh signaling in definitive hematopoiesis, two recent papers have demonstrated that the Hh pathway is dispensable for adult HSC function and hematopoiesis using adult mice where Smo was conditionally deleted. 29, 30 As opposed to most of the previously discussed studies, in which embryonic Hh signaling was affected, both of these studies used Mx-cre mice to delete Smo in adult mice upon poly-I-C injections. In addition, Hofmann et al. 30 further showed that the pharmacological inhibition of Hh signaling using a small molecule had no effect on normal hematopoiesis in adult mice. In agreement with these phenotypic and functional studies, Gao et al. 29 found by gene expression profiling that HSC-specific gene expression signature was preserved in the Smo-deficient HSC. Furthermore, using a Smo gain-of-function model (SmoM2), again driven by Mx-Cre, the authors reported that the Hh hyperactivation did not lead to expansion of HSC.
Hh pathway and malignancies
The first suggestion of the importance of Hh signaling in tumorigenesis came from the observation of Gli involvement in glioma development. 31 A definitive link between the Hh pathway and cancer was established by the identification of somatic mutations of Ptch in patients with Gorlin syndrome and basal cell nevus syndrome as these individuals are highly predisposed to develop advanced basal cell carcinoma (BCC), medulloblastoma (MB) and rhabdomyosarcoma. Moreover, Ptch and Smo mutations were identified in sporadic BCCs and MB (Figure 2a) . [32] [33] [34] In addition to mutations in components of the Hh signaling cascade, several cancers have been shown to abnormally express the Hh ligands and activate the Hh pathway in both an autocrine and paracrine manner, depending on the tumor type. Autocrine activation, in which the tumor cells produce and respond to their own Hh ligands, has been reported in a wide variety of tumors, such as small cell lung cancer, pancreatic, colon, prostate, breast cancers, glioblastoma, melanomas, chronic myeloid leukemia (CML) and B-cell lymphoma (Figure 2b) . 25, 26, [35] [36] [37] [38] [39] [40] Paracrine activation occurs when the tumor cells secrete Hh ligands, which stimulate the Hh pathway in stroma cells that in turn produce factors that sustain tumor growth. This mechanism of action has been suggested for pancreatic and colon cancers (Figure 2c) . [41] [42] [43] In addition, stroma cells in non-Hodgkin lymphoma and multiple myeloma have been found to secrete Hh ligands that promote the survival of the malignant cells, in an inverse paracrine manner (Figure 2d ). Focusing in on hematological malignancies, many publications have reported the role of the Hh pathway in CML, leukemia, lymphoma and multiple myeloma. In contrast, some groups have also reported that the Hh pathway is not required for Notch-dependent T-cell acute lymphoblastic leukemia 29 and MLL-AF9-induced acute myeloid leukemia. 30 The Hh pathway has been suggested to be activated in multiple myeloma stem cells and that stimulation of these cells with Hh ligand promotes the expansion of multiple myeloma stem cells without differentiation, suggesting an inverse paracrine mechanism of action of the Hh pathway. 44 Similarly, Dierks et al. 45 reported that the Hh ligands are produced by stroma cells in the BM, spleen and lymph nodes and these allow the survival and expansion of lymphoma cells in vitro and in vivo. The activation of the Hh pathway could be due to amplification of the Shh ligand in ALK-positive anaplastic large cell lymphoma cells. In the same cells, the NPM-ALK fusion gene activates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which stabilizes the Gli1 protein, suggesting a synergistic effect between the Hh and PI3K pathways. 46 Recently, the same group reported that diffuse large B-cell lymphoma cells express the Hh signaling proteins and that the inhibition of the Hh pathway results in cell-cycle arrest and apoptosis in diffuse large B-cell lymphoma cells of GC type and ABC type, respectively. These results suggested an autocrine activation of the Hh pathway in diffuse large B-cell lymphoma. 36 Likewise, Lin et al. 47 suggested an autocrine activation of the Hh pathway in B-cell acute lymphoblastic leukemia. The expression of the Hh genes was found in standard and high-risk subtypes of B-cell acute lymphoblastic leukemia; in addition, the authors reported that the developmental pathway was responsible for the self-renewal of the B-cell acute lymphoblastic leukemia cells. All these reports suggest that Hh inhibition may be a valid approach in different hematological malignancies.
CML and a CML stem cell
The most clinically relevant and well-defined hematological stem cell disease linked with the Hh signaling pathway is CML. CML is a myeloproliferative disease clinically characterized by the unregulated clonal growth of predominantly myeloid cells, which eventually present as an accelerated phase, and a blast crisis, which is indistinguishable from acute leukemia and carries a very poor prognosis (reviewed in Sawyers 48 ). Molecularly, CML is characterized by the Philadelphia chromosome (Ph þ ), a 9;22 translocation which leads to the BCR-ABL fusion protein, a constitutively activated tyrosine kinase. [49] [50] [51] [52] Imatinib mesylate (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is a tyrosine kinase inhibitor with activity against BCR-ABL, c-Kit and PDGFR which has revolutionized the treatment and prognosis of patients with CML. [53] [54] [55] Imatinib has improved the 5-year survival of CML patients to 89%, 53 with most patients obtaining a major molecular response as defined by a 3-log reduction in BCR-ABL transcript levels. This reflects a rapid initial clearance of mature CML progeny; however, the kinetics of BCR-ABL transcript reduction then slows considerably and only a minority of patients reach PCR undetectable levels even after prolonged treatment, though the number increases over time. 56 Even then, such complete molecular responses do not necessarily translate into an elimination of all CML cells. In the largest series reported to date, in the STIM (Stop Imatinib) trial, even patients that that were PCR negative for 2 years had a substantial risk of reoccurrence if imatinib was discontinued, 57 with 61% of patients relapsing, mostly in o6 months.
Fortunately, the relapsed patients retained sensitivity to imatinib on reinitiation of therapy. Although 39% of patients remained in molecular remission, median follow-up was a relatively short 24 months. Second-generation BCR-ABL inhibitors, such as dasatinib (Sprycel; Bristol-Myers Squibb (BMS), New York City, NY, USA) and nilotinib (Tasigna; Novartis), are also now in clinical use and show improved disease control. However, in view of the limited data concerning the long-term outcomes of discontinuing imatinib and second-generation inhibitors, the optimal duration of therapy remains a matter of debate and it is currently recommended that patients continue therapy for life.
Although not universally accepted, it is currently thought that the existence of a CML stem cell is most consistent with these clinical observations. The BCR-ABL þ CML stem cell is thought to be a relatively primitive cell that maintains the leukemia, yet itself is less susceptible to imatinib treatment than its more mature progeny, for various reasons. Experimental support for this hypothesis has existed for 430 years, when elegant work implicated a multipotent primitive cell as the source of CML. 58 This work cleverly utilized female CML patients with heterozygous isoforms of the X-linked G6PD (glucose-6-phosphate dehydrogenase) gene to determine clonality. Because of X-inactivation, each cell in females expresses only one allele of G6PD, but since X-inactivation is random, tissues, including normal blood cells, express a mixture of both isoforms. This was not true of the CML patients' granulocytes, demonstrating clonality, but surprisingly, their erythrocytes, platelets and macrophages also carried a single enzyme phenotype, implying an affected primitive cell still capable of pluripotency, but also with a growth advantage over normal hematopoiesis.
Unfortunately, the first evidence that CML contained stem cells capable of engrafting immunocompromised recipients was seen in humans, not in mice, when physicians tried to support severely neutropenic children treated for acute lymphoblastic leukemia with leukocyte infusions. 59, 60 Because neutrophils are very short lived, the most practical source was to leucophores people with very high granulocyte counts, that is, patients with CML. The authors of these reports noted persistent mitosis of the Ph þ -transfused cells, as well as engraftment of CML and graft vs host disease attributed to the infusions in a bone marrow transplant patient.
These clinical observations are supported by extensive xenotransplantation work in immunocompromised murine models, in which peripheral blood or BM from CML patients was capable of engrafting severe combined immunodefiency or nonobese diabetic/severe combined immunodeficiency mice. 61, 62 Interestingly, the mice engrafted both normal and CML stem cells from chronic phase CML patients, but engrafted predominately from CML stem cells from blastic phase CML patients. Refining this work, a G0 quiescent CD34 þ population was identified from CML patients and was capable of engrafting mice with CML. 63 Evidence suggests that it is this primitive CML stem cell population that persists despite BCR-ABL inhibition, and various mechanisms have been proposed to explain these observations. They can be grouped into two broad categories. First are mechanisms in which BCR-ABL is still central to CML stem cell survival; however, current inhibitors are ineffective in the stem cell context. Proposed mechanisms include efflux pumps, lack of transporters, quiescence, microenvironment, increased BCR-ABL expression or ABL mutations. The second category is the idea that CML stem cell survival is independent of BCR-ABL activity and perhaps dependent on other pathways, which may be similar or dissimilar to normal HSCs (Jabbour et al., 64 le Coutreet et al., 65 Picard et al., 66 Gambacorti-Passerini et al., 67 Jorgensen et al., 68 Mahon et al., 69, 70 Thomas et al., 71 Galimberti
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Hedgehog pathway in normal and malignant hematopoiesis BG Mar et al et al., 72 Jordanides et al., 73 Crossman et al., 74 Komarova et al., 75 Michor et al., 76 Roeder et al., 77 Holtz et al., 78 Graham et al. 79 and reviewed in Chen et al. 80 and Quintas-Cardama et al. 81 ). Which of these mechanisms is most important is a matter of controversy, and will not be reviewed here, but has great implications on which therapeutic approaches will ultimately prove effective in eliminating persistent disease.
Supporting the second category, a very recent article by Corbin et al. 82 demonstrated in primary CML patient cells that BCR-ABL could be inhibited in the CD34 þ CD38 À stem fraction to the same degree as the CD34 þ CD38 þ progenitor fraction in vitro and that this inhibition did not affect the growth or survival of CML stem cells when grown with cytokine support. This was true whether BCR-ABL inhibition was achieved with imatinib, dasatinib or nilotinib and was also true in the quiescent cell fraction. If CML stem cells are truly insensitive to BCL-ABL inhibition, then additional pathways supporting their growth must be exploited in order to eliminate them. Several candidate pathways have been proposed, including Wnt/b-catenin, Alox5, Pten, FoxO, and of course, the Hedgehog pathway (reviewed in Chen et al.
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). In the same year, Dierks et al., 25 showed conceptually similar results using different genetic models as well as cyclopamine inhibition. When transduced with BCR-ABL retrovirus and transplanted into mice, Smo À/À fetal liver cells caused disease in only 60% of recipients, again with long latency, compared with Smo þ / þ cells, where all recipient mice were affected rapidly. This effect was even more pronounced in the secondary recipients, where no mice receiving Smo À/À cells developed disease, even after 9 months of observation. In contrast to the Zhao paper, this paper used a combination of cyclopamine and nilotinib, and showed they had an additive effect in reducing colony forming units, and in mice, the combination took longer to relapse after discontinuation of therapy than nilotinib alone.
Hedgehog signaling in CML stem cells
Complementary to these studies, Irvine et al. 83, 84 reported, in abstract form, that the small-molecule Smo antagonist NVP-LDE225 (Novartis Pharmaceuticals) in primary CML cells in vitro caused a significant reduction in secondary colony formation and replating efficacy with increasing concentrations of drug. A combination of NVP-LDE225 and nilotinib reduced replating efficiency even further and also improved survival after drug discontinuation in mice, similar to the cyclopamine results. Further supporting this approach, also in abstract form, Schairer et al. 85 reported that another novel Smo antagonist, PF-04449913, when combined with dasatinib, showed decreases in primary CML cell engraftment in Rag2 À/À gc À/À mice and eradication of the cells' ability to form myeloid sarcomas. Taking a more clinical tack, again in abstract form, Cea et al. 86 analyzed 20 patients with chronic phase CML and found that increases in Hh activity tended to precede the development of Abl kinase mutations, particularly with the gatekeeper mutation T315I.
In summary, early studies have shown promising results and have identified inhibition of Hh signaling as a potential therapeutic approach in CML via specific activity against the CML stem cells, which are difficult to eradicate with BCR-ABL inhibition alone. Additionally, monitoring for Hh pathway activity may have prognostic value; however, much more work needs to done to translate these ideas to the clinic.
Clinical experience with Hh pathway inhibitors
The demonstration of the importance of the Hh pathway in different cancer types, as discussed above, suggested the possibility of developing targeted therapy against this pathway for cancer patients, either as monotherapy or in combination with other therapies. The first indication that Smo could be targeted came with the isolation of a compound called cyclopamine from corn lily (Veratrum califomicum), which causes an unusual fetal birth defect. Cyclopamine was named for the one-eyed lambs which were born to sheep which grazed on wild corn lily at a farm in Idaho. The Hh pathway has increasingly become as area of extensive research in cancer by many pharmaceutical companies and universities leading to the discovery of novel Hh pathway inhibitors with better pharmacological properties than cyclopamine. The majority of Hh pathway inhibitors reported to date target Smo and several of these agents have advanced into human clinical trials (Table 1) . Table 1 Hh pathway inhibitors currently in clinical trials The first report of the identification of a Smo synthetic smallmolecule inhibitor came from Curis (Lexington, MA, USA) in 2003. 87 This compound, called Cur61414, was shown to suppress proliferation and induce apoptosis in an in vitro BCC model. After intense optimization efforts, researchers at Curis and Genentech (San Francisco, CA, USA) identified the leading compound GDC-0449. Encouraging results from the phase I clinical trial in patients with metastatic and locally advanced BCC were reported. 88 Thirty-three BCC patients were treated orally with GDC-0449 (Vismodegib) at doses of 150, 270 or 540 mg daily for a median of 9.8 months. Among the treated patients, 18 patients achieved objective tumor responses, including 2 complete responses and 16 partial responses. In addition, the results from a patient with refractory MB, with extracranial disease, have been reported. 89 This MB patient showed a dramatic metabolic response on fluorodeoxyglucosepositron emission tomography, following treatment with GDC-0449 for 2 months, but this effect was transient, as the patient relapsed after just 1 month. Molecular profiling of one of the metastasis showed the appearance of a single point mutation in Smo (D473H) that prevented the binding of GDC-0449, therefore, conferring resistance to treatment. 90 This compound is currently being tested in several phase II and III clinical trials in different cancer indications as a single agent or in combination with other therapies.
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Novartis developed the small-molecule Smo inhibitor NVP-LDE225 for oral and topical use. 91 Phase I clinical trial results for oral NVP-LDE225 were recently reported at a European Society for Medical Oncology meeting in 2010. NVP-LDE225 is well tolerated and has a favorable pharmacokinetic profile. It has demonstrated dose-and exposure-dependent target inhibition, as measured by Gli1 mRNA expression in skin. Moreover, preliminary evidence of anti-tumor activity was observed in two BCC patients, one (metastatic BCC) with stable disease for 418 months and the second BCC patient with complete clinical and pathological response. In addition, responses were observed in two recurrent MB patientsFone patient with cerebellar disease achieved a partial response after 2 months of therapy, which was maintained for 4 months; and the second patient with metastatic bone disease experienced a partial metabolic response on fluorodeoxyglucose-positron emission tomography, associated with improvement in bone pain and maintained for B10 months. 92 The mechanism of resistance developed by these patients is not known; however, studies in MB mouse models demonstrated potential ways of acquiring resistance to NVP-LDE225 and other Smo inhibitors. 93 Molecular analysis of the murine tumors revealed multiple mechanisms of resistance. Reactivation of the Hh pathway was observed in the resistant tumors through Gli2 amplification or Smo mutations, but these two different mechanisms did not coexist in the same tumor. In addition, through gene expression profiling, the authors showed that PI3K signaling was upregulated in the majority of the resistant tumors and that the combination of the Smo and PI3K inhibitors markedly delayed the appearance of resistance. As disease progression has been observed following a period of response to Smo inhibitor treatments, these results suggest the potential clinical utility of combining PI3K and Hh pathwaytargeting agents in MB as a therapeutic strategy for mitigating acquired resistance. In addition, Novartis has generated a second Smo inhibitor, NVP-LEQ506, that is currently being tested in phase I trials.
Infinity (Cambridge, MA, USA) has developed the cyclopaminederived Smo inhibitor, IPI-926. This compound was evaluated in an MB allograft model and showed complete regression that was maintained for 21 days after the termination of treatment. 94 IPI-926 entered a phase I clinical trial in 2008 in patients with solid tumors and has been reported to be generally well tolerated. 95 Exelixis (San Francisco, CA, USA) in partnership with BMS developed the Smo inhibitor XL-139 (BMS-833923). The first-inman phase I clinical data showed that the compound was well tolerated and was able to inhibit Gli1 expression in skin. In addition, disease stabilization in a patient with MB and a confirmed partial response in a basal cell nevoid syndrome patient have been reported. 
Conclusion
Although the role of the Hh pathway in primitive vasculogenesis has been established using several genetic models, its function in definitive hematopoiesis is still controversial, but may be highly timing dependent. Interestingly, many pharmaceutical companies have developed Hh inhibitors, which are now undergoing clinical evaluation, mainly in solid tumors indications, and at this time, none of these agents have been reported to show hematopoietic toxicity, so far supporting the idea that these inhibitors may not affect adult normal hematopoiesis and may be able to be used in combination with myelosuppressive therapies with minimal or no concerns about overlapping hematological toxicities.
The evidence for the role for Hh in hematological malignancies is limited but rapidly developing. The most evidence is in CML, perhaps the most well-defined HSC disorder, where concurrent BCR-ABL and Hh pathway inhibition shows promising data in the preclinical setting. This has provided the rationale for the initiation of exploratory clinical trials combining Smo pathway inhibitors with ABL kinase inhibitors in CML. Though much work remains to be done in preclinical models to guide the optimal sequence for combining these agents in CML, preliminary results from the ongoing trials may ultimately provide the proof-of-concept of the effectiveness of this approach.
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